publication venue for A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.. 142:62-69. 2016 Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study.. 140:277-284. 2016 Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study.. 136:542-548. 2015 A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.. 133:433-438. 2014 The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.. 133:584-590. 2014 A pilot randomized control trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors.. 132:154-158. 2014 Endometrial cancer and a family history of cancer.. 130:334-339. 2013 Comparison of gene expression patterns between avian and human ovarian cancers.. 120:256-264. 2011 Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.. 114:3-11. 2009 GPR30 predicts poor survival for ovarian cancer.. 114:465-471. 2009 Summary of the 2015 American Association for Cancer Research (AACR) Annual Meeting. 2015 No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 2015
